Premium
Treatment of hirsutism in polycystic ovary syndrome with bromocriptine
Author(s) -
MURDOCH A. P.,
MCCLEAN K. G.,
WATSON M. J.,
DUNLOP W.,
TAYLOR P. KENDALL
Publication year - 1987
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.1987.tb03105.x
Subject(s) - bromocriptine , hirsutism , polycystic ovary , androstenedione , medicine , testosterone (patch) , sex hormone binding globulin , endocrinology , ovary , hormone , prolactin , androgen , insulin , insulin resistance
Summary The value of bromocriptine in the treatment of hirsutism in polycystic ovary syndrome (PCO) was assessed subjectively and photographically in a double‐blind trial in 22 women studied for 1 year. Menstrual frequency was recorded. Circulating concentrations of oestradiol, oestrone, testosterone, androstenedione, and sex hormone binding globulin (SHBG) were determined before treatment and after 6 and 12 months therapy. On the same occasions gonadotrophin concentrations (mean of 24 samples) and their response to 100 μg LHRH were determined. No evidence was found to support a therapeutic role for bromocriptine in the treatment of hirsutism or menstrual regulation in PCO. No biochemical changes were seen specific to bromocriptine therapy.